0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV788.63%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier26DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.69Leverage Ratio--Theta--Rho--Eff Leverage--Vega
DarioHealth Stock Discussion
Dario Signs Four New Employer Contracts Across Full Product Suite
DarioHealth (Nasdaq: DRIO) has secured four new self-insured employer contracts, expected to go live in Q1 2025. These contracts cover Dario's complete platform suite, with clients opting for multi-condition offerings rather than single-condition solutions. The company projects to achieve approximately 25 new client signings in 2024, representing a 35% growth in client base compared to 2023.
These new ...
Dario Publishes New Research Revealing How Physical Activity Mediates the Impact of Depression on Blood Glucose Levels in Individuals with Diabetes or Prediabetes
DarioHealth Corp. (Nasdaq: DRIO) has published a new study in Frontiers in Endocrinology, demonstrating the effectiveness of its cardiometabolic solution for individuals with diabetes or prediabetes and depression. The research, involving 989 users over 12 months, reveals:
Members with depression showed highe...
DarioHealth-New Contract With National Employer to Provide Cardiometabolic Solution With Integrated Support for Glp-1S to Employees Beginning in Q3
Dario Demonstrates 12 Months of Sustained Healthy Behavior Change for Members Taking a GLP-1
New research presented by DarioHealth at the 84th Annual ADA Scientific Sessions demonstrates the efficacy of their digital health platform in sustaining behavior change for members taking GLP-1 medications. Data over a 12-month period show significant improvements in healthy lifestyle tracking and blood glucose control. Notably, 31% of Type 2 diabetes members achieved results ...
DarioHealth Q1 Net Loss $(7.2)M Compared To $(12.8)M YoY
DarioHealth Corp Qtrly Shr Loss $0.20
DarioHealth Q1 Revenue USD 1.791 Million
Moomoo 24/7· 3 mins ago
No comment yet